Bayer's Vividion Initiates Dosing in Early-Stage Cancer Study
BAYRY subsidiary Vividion Therapeutics doses the first patient in a phase I study on VVD-159642 to treat advanced solid ...
Fierce Biotech1d
Relay Therapeutics starts third layoff wave in 1 year, shedding 70 staffers
Relay Therapeutics has laid off about 70 employees, the biotech's third round of cuts in less than a year.  | Relay ...
BioSpace1d
Lilly Throws Sangamo a Lifeline with Pact Worth Potential $1.4B+
Sangamo, which has been having cash problems, will receive $18 million upfront in licensing fees for its AAV capsid that has ...
Clinical Trials Arena1d
Vividion begins subject dosing in trial of RAS-driven cancer treatment
Vividion Therapeutics has dosed the first subject in a Phase I trial of an oral inhibitor, VVD-159642, aimed at treating ...
Medical Dialogues1d
Bayer AG arm Vividion Therapeutics doses first patient in Phase I study of RAS-PI3Kα Inhibitor for advanced solid tumors treatment
Vividion Therapeutics, Inc. has announced that the first patient has been dosed in a Phase I clinical trial evaluating ...
Precision Medicine Online2d
Vividion Begins Phase I Trial of RAS-PI3Kα Inhibitor in Advanced Solid Tumors
The firm believes VVD-159642 has the potential to treat a broad patient population, including those with RAS- and HER2-overexpressed tumors.
Vividion Therapeutics Doses First Patient in Phase I Study of RAS-PI3Kα Inhibitor for Treatment of Advanced Solid Tumors
Vividion Therapeutics, Inc. (Vividion) today announced that the first patient has been dosed in a Phase I clinical trial ...
BBOT Announces First Patient Dosed with BBO-11818, a PanKRAS Dual Inhibitor, in the Phase 1 KONQUER-101 Trial for Advanced Solid Tumors
TheRas, Inc. d/b/a BridgeBio Oncology Therapeutics ("BBOT" or the "Company"), a clinical-stage biopharmaceutical company ...
Celcuity To Present at Upcoming Needham and Stifel Investor Conferences
A fireside chat at the 24 th Annual Needham Virtual Healthcare Conference at 11:00 a.m. ET on Thursday, April 10, 2025. A live webcast will be available using this weblink: ...
The Manila Times5d
Celcuity Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
VIKTORIA-2 Phase 3 remains on track to enroll its first patient in Q2 2025 Presented encouraging preliminary overall survival ...
Cogent Biosciences Announces Multiple Poster Presentations at 2025 American Association for Cancer Research (AACR) Annual Meeting
Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced four preclinical poster presentations at ...